Breast Neoadjuvant

SWOG S2212

Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study

---

URCC 19075 **MBMC ONLY**

Multi-Center Randomized Controlled Phase II Trial of Exercise to Treat Chemotherapy-Induced Peripheral Neuropathy (CIPN)

---

URCC-21038

Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting

---

EA1181 (CompassHER2-pCR) *****Upcoming Closure to Accrual 10/12/23 4pm cst**** ****ER-NEGATIVE COHORT CLOSED TO ACCRUAL EFFECTIVE MAY 18, 2023*** ****The subset of patients with HER2-positive and ER-positive breast cancer with tumors 2.1-3.0 cm and node-negative is CLOSED TO ACCRUAL EFFECTIVE JULY 27, 2022****

Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response Part 1 Component of: The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer)

---

URCC 18007

Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue

---